Quote Overview

Stock Activity

Open	111.30
Day Low	108.27
Day High	111.53
52 Wk Low	89.00
52 Wk High	213.91
Avg. Volume	1,548,534
Market Cap	17.69 B
Dividend	NA
Beta	1.20

Key Earnings Data

Earnings ESP	-29.69%
Most Accurate Est	0.08
Current Qtr Est	0.11
Current Yr Est	0.87
Exp Earnings Date	8/14/24
Prior Year EPS	0.86
Exp EPS Growth (3-5yr) NA
Forward PE	127.67
PEG Ratio	NA

Medical » Medical - Biomedical and Genetics

Research Reports for ILMN

All Zacks’ Analyst Reports

Premium Research for ILMN

Style Scores D Value B Growth D Momentum D VGM
Zacks Rank	Hold 3
Zacks Industry Rank	Top 34%(86 out of 252)
Zacks Sector Rank	Top 25% (4 out of 16)
Earnings ESP	-29.69%
Research Reports for ILMN Analyst \| Snapshot

( = Change in last 30 days)

View All Zacks Rank #1 Strong Buys

Premium Research: Industry Analysis

Top Peers	Symbol	Zacks Rank
Illumina	ILMN
Basilea Pharmaceutica	BPMUF
ALX Oncology Holdings	ALXO
AN2 Therapeutics	ANTX
ANI Pharmaceuticals	ANIP
Acumen Pharmaceuticals	ABOS
Adlai Nortye Ltd. Sponsored ADR	ANL

See all Medical - Biomedical and Genetics Peers

Zacks News for ILMN

No Record found.

Company Summary

San Diego, CA.-based Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies.
Illumina generates revenue from two segments:

Product revenues (84% of total revenues in 2023, down 4.2% from 2022) consist of sales proceeds from the consumables and instruments used in genetic analysis.

Service and other revenue (16%, up 13.6%) primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and cancer detection testing services related to the GRAIL business.

Next-Generation Sequencing (NGS)

Illumina’s portfolio of sequencing platforms represents a family of systems that are designed to meet the workflow, output, and accuracy demands of a full range of sequencing applications. The company’s MiSeq sequencing system is a low-cost desktop sequencing system that provides individual researchers with rapid turnaround time, high accuracy and streamlined workflow. NextSeq 500, launched in January 2014, provides flexibility from whole genome sequencing to targeted panels in a desktop platform. The HiSeq 2500 sequencing system allows customers to sequence an entire human genome in approximately a day.

In 2022, Illumina announced its new production-scale sequencing systems, NovaSeq X Series (NovaSeq X and NovaSeq X Plus), which can sequence a human genome for as little as $200.

Following the acquisition of GRAIL in 2021, from Jan 1, 2023, the company reports through two segments — Core lllumina (relates to the core operations) and GRAIL. In 2023, Core Illumina comprised 98.5% of the company’s consolidated revenues, while GRAIL service and other revenue comprised the rest 1.5%.